IRIDEX Corporation (IRIX) Presents At Stifel Healthcare Conference - Slideshow

Glaucoma Market and Solution - The global glaucoma market is a $5 billion market [7] - IRIDEX offers MicroPulse Transscleral Laser Therapy as a non-incisional solution for glaucoma, targeting ciliary body tissue to reduce IOP [11] - Clinical outcomes show a 39% IOP reduction at a mean of 78 months follow-up [8, 14] - Over 120,000 MicroPulse procedures have been performed globally since 2015 [16] Market Opportunity and Penetration - The U S probe opportunity is estimated at $500 million [12] - The Rest of World (ROW) probe opportunity is estimated at $700 million [13] - IRIDEX's U S 2019 MP3 probe run rate is 25,000 [12] - IRIDEX's ROW 2019 MP3 volume run rate is 25,000 [13] Financials and Growth - 2019 Revenue Guidance is $41 million to $44 million [27] - As of September 28, 2019, IRIDEX had $12 9 million in cash and no debt [27]